
Big Pharmas ‘line up’ for BasgenBio’s AI drug target tech as it nears $70 mil. licensing deal: CEO
Global drugmakers are sitting on a pipeline full of drugs, but not enough validated targets. “You can manipulate a target all you want, but if the disease doesn’t improve, it’s useless,” says BasgenBio CEO Kim Ho. The Korean biotech believes it has the …